ARID1A mutation in endometrial cancer: a review

Endometrial carcinoma is the most frequent gynecological malignancy and a leading cause of cancer death in women worldwide. ARID1A, a gene participated in chromatin remodeling, is an emerging tumor suppressor gene. Accumulating evidence has reported somatic inactivating mutations of ARID1A and loss of its expression in many types of human cancers, especially in endometrium-derived tumors. The high prevalence of somatic mutations in endometrial cancers indicates a pivotal role of ARID1A in their development. Understanding the roles of ARID1A in the pathogenesis of endometrial carcinoma is fundamental for future translational studies aimed at designing new diagnostic tests for early detection and identifying critical molecular targets for new therapeutic interventions.

ARID1A; Mutation; Endometrial cancer; ARID1B.

[1] Ho L., Crabtree G.R.: “Chromatin remodelling during development”. Nature, 2010, 463, 474.

[2] Clapier C.R., Cairns B.R.:”The Biology of Chromatin Remodeling Complexes”. Annu. Rev. Biochem., 2009, 78, 273.

[3] Beausoleil S.A., Gygi S.P.: “Large-scale characterization of HeLa cell nuclear phosphoproteins”. Proc. Natl. Acad. Sci. U S A., 2004, 101, 12130.

[4] Wilsker D., Probst L., Wain H.M, Maltais L., Tucker P.W., Moran E.: “Nomenclature of the ARID family of DNA-binding proteins”. Genomics, 2005, 86, 242.

[5] Dallas P.B., Pacchione S., Wilsker D., Bowrin V., Kobayashi R., Moran E.: “The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity”. Mol. Cel. Biol., 2000, 20, 3137.

[6] Reisman D., Glaros S., Thompson E.A.: “The SWI/SNF complex and cancer”. Oncogene, 2009, 28, 1653.

[7] Phelan, Michael L., Saïd, Narlikar, Geeta J., Kingston R.E.:”Reconstitution of a Core Chromatin Remodeling Complex from SWI/SNF Subunits”. Mol. Cel., 1999, 3, 247.

[8] Wang X., Nagl N.G., Wilsker D., Scoy M.V., Pacchione S., Yaciuk P., et al.: “Two related ARID family proteins are alternative subunits of human SWI/SNF complexes”. Biochem. J., 2004, 383, 319.

[9] Saha A., Wittmeyer J., Cairns B.R.:”Chromatin remodelling: the industrial revolution of DNA around histones”. Nat. Rev. Mol. Cell. Biol., 2006, 7, 437.

[10] Lorch Y., Maierdavis B., Kornberg R.D.: “Mechanism of chromatin remodeling”. Proc. Natl. Acad. Sci. U S A, 2010, 107, 3458.

[11] Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P.,et al.: “Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma”. Nature, 2011, 469, 539.

[12] Jones S., Li M., Parsons D.W., Zhang X., Wesseling J., Kristel P.,et al.: “Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types”. Human. Mutat., 2012, 33, 100.

[13] Zang Z.J., Cutcutache I., Poon S.L., Zhang S.L., Mcpherson J.R., Tao J.,et al.: “Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes”. Nat. Genet., 2012, 44, 570.

[14] Agrawal N., Jiao Y., Bettegowda C., Hutfless S.M., Wang Y., David S., et al.: “Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma”. Cancer. Discov., 2012, 2, 899.

[15] Streppel M.M., Lata S., DelaBastide M., Montgomery E.A., Wang J.S., Canto M.I., et al.: “Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett’s esophagus”. Oncogene, 2013, 33, 347.

[16] Huang J., Deng Q., Wang Q., Li K.Y., Dai J.H., Li N., et al.: “Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma”. Nat. Genet., 2012, 44, 1117.

[17] Fujimoto A., Totoki Y., Abe T., Boroevich K.A., Hosoda F., Nguyen H.H., et al.: “Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators”. Nat. Genet., 2012, 44, 760.

[18] Imielinski M., Berger A., Hammerman P., Hernandez B., Pugh T., Hodis E., et al.: “Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing”. Cell, 2012, 150, 1107.

[19] Biankin A.V., Waddell N., Kassahn K.S., Gingras M.C., Muthuswamy L.B., Johns A.L., et al.: “Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes”. Nature, 2012, 491, 399.

[20] Cornen S., Adelaide J., Bertucci F., Finetti P., Guille A., Birnbaum D.J., et al.: “Mutations and deletions of ARID1A in breast tumors”. Oncogene, 2012, 31, 4255.

[21] Stephens P.J., Tarpey P.S., Davies H., Van L.P., Greenman C., Wedge D.C., et al.: “The landscape of cancer genes and mutational processes in breast cancer”. Nature, 2012, 486, 400.

[22] Jones S., Wang T.L., Iem S., Mao T.L., Nakayama K., Roden R., et al.: “Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma”. Science, 2012, 330, 228.

[23] Wiegand K.C., Shah S.P., Alagha O.M., Zhao Y., Tse K., Zeng T., et al.: “ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas”. N. Engl. J. Med., 2010, 363, 1532.

[24] Guan B., Mao T.L., Panuganti P.K., Kuhn E., Kurman R.J., Maeda D., et al.: “Mutation and loss of expression of ARID1A in uterine lowgrade endometrioid carcinoma”. Am. J. Surg. Pathol., 2011, 35, 625.

[25] Le G.M., O’Hara A.J., Rudd M.L., Urick M.E., Hansen N.F., O’Neil N.J., et al.: “Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes”. Nat. Genet., 2012, 44, 1310.

[26] Mcconechy M.K., Ding J., Cheang M.C., Wiegand K., Senz J., Tone A.A., et al.: “Use of mutation profiles to refine the classification of endometrialcarcinomas”. J. Pathol., 2012, 228, 20.

[27] Hoang L.N., Mcconechy M.K., Meng B., Mcintyre J.B., Ewanowich C., Gilks C.B., et al.: “Targeted mutation analysis of endometrial clear cell carcinoma”. Histopathology, 2015, 66, 664.

[28] Fadare O., Renshaw I.L., Liang S.X.: “Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment”. J. Cancer, 2012, 3, 129.

[29] Fadare O., Gwin K., Desouki M.M., Crispens M.A., Jones H.W., Khabele D., et al.: “The Clinicopathologic Significance of p53 and BAF-250a (ARID1A) Expression in Clear Cell Carcinoma of the Endometrium”. Mod. Pathol., 2013, 26, 1101.

[30] Guan B., Gao M., Wu C.H., Wang T.L., Shih I.M., et al.: “Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions”. Neoplasia, 2012, 14, 986.

[31] Mamo A., Cavallone L., Tuzmen S., Chabot C., Ferrario C., Hassan S., et al.: “An integrated genomic approach identifies ARID1A as a candi date tumor-suppressor gene in breast cancer”. Oncogene, 2011, 31, 2090.

[32] Wiegand K.C., Lee A.F., Al-Agha O.M., Chow C., Kalloger S.E., Scott D.W., et al.: “Loss of BAF250a (ARID1A) is frequent in highgrade endometrial carcinomas”. J. Pathol., 2011, 224, 328.

[33] Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I.B., et al.: “Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma”. Nat. Genet., 2012, 44, 694.

[34] Gao X., Tate P., Hu P., Tjian R., Skarnes W.C., Wang Z.:”ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a”. Proc. Natl. Acad. Sci. U S A., 2008, 105, 6656.

[35] Mao T.L., Ardighieri L., Ayhan A., Kuo K.T., Wu C.H., Wang T.L.,et al.: “Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma”. Am. J. Surg. Pathol., 2013, 37, 1342.

[36] Gagnon V., Mathieu I., Sexton E., Leblanc K., Asselin E., et al.: “AKT involvement in cisplatin chemoresistance of human uterine cancer cells”. Gynecol. Oncol., 2004, 94, 785.

[37] Flores-Alcantar A., Gonzalez-Sandoval A., Escalante-Alcalde D., Lomelí H.: “Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle”. Cell. Tissue. Res., 2011, 345, 137.

[38] Guan B., Wang T.L., Shih I.M.:”ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers”. Cancer. Res., 2011, 71, 6718.

[39] Nagl N.G. Jr., Wang X., Patsialou A., Van S.M., Moran E.: “Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control”. EMBO J., 2007, 26, 752.

[40] Luo B., Cheung H.W., Subramanian A., Sharifnia T., Okamoto M., Yang X., et al.: “Highly parallel identification of essential genes in cancer cells”. Proc. Natl. Acad. Sci. U S A., 2008, 105, 20380.

[41] Bosse T., ter Haar N.T., Seeber L.M., Pj V.D., Hes F.J., Vasen H.F., et al.: “Loss of ARID1A expression and its relationship with PI3KAkt pathway alterations, TP53 and microsatellite instability in endometrial cancer”. Mod. Pathol., 2013, 26, 1525.

[42] Allo G., Bernardini M.Q., Wu R.C., Shih I.M., Kalloger S., Pollett A., et al.: “ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas”. Mod. Pathol., 2013, 27, 255.

[43] Burgart L.J.: “Testing for defective DNA mismatch repair in colorectal carcinoma: a practical guide”. Arch. Pathol. Lab. Med., 2005, 129, 1385.

[44] Esteller M., Catasus L., Matias-Guiu X., Mutter G.L., Prat J., Baylin S.B., et al.: “hMLH1 Promoter hypermethylation is an early event in human endometrial tumorigenesis”. Am. J. Pathol., 1999, 155, 1767.

[45] Llobet D., Pallares J., Yeramian A., Santacana M., Eritja N., Velasco A., et al.: “Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints”. J. Clin. Pathol., 2009, 62, 777.

[46] Liang H., Cheung L.W., Li J., Ju Z., Yu S., Stemke-Hale K., et al.: “Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer”. Genome. Res., 2012, 22, 2120.

[47] Cheung L.W., Hennessy B.T., Li J., Yu S., Myers A.P., Djordjevic B., et al.: “High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability”. Cancer. Discov., 2011, 1, 170.

[48] Hoang L.N., Mcconechy M.K., Köbel M., Han G., Rouzbahman M., Davidson B., et al.: “Histotype-genotype correlation in 36 high-grade endometrial carcinomas”. Am. J. Surg. Pathol., 2013, 37, 1421.

[49] Huang H.N., Lin M.C., Tseng L.H., Chiang Y.C., Lin L.I., Lin Y.F., et al.: “Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression”. Histopathology, 2015, 66, 517.

[50] Guan B., Rahmanto Y.S., Wu R.C., Wang Y., Wang Z., Wang T.L., et al.: “Roles of Deletion of Arid1a, a Tumor Suppressor, in Mouse Ovarian Tumorigenesis”. J. Natl. Cancer. Inst., 2014, 106, 766.

[51] Tanwar P.S.: “PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression”. Carcinogenesis, 2013, 34, 893.

[52] Wu J.N., Roberts C.W.: “ARID1A mutations in cancer: another epigenetic tumor suppressor?”.Cancer. Discov., 2013, 3, 35.

[53] Helming K.C., Wang X., Wilson B.G., Vazquez F., Haswell J.R., Manchester H.E., et al.: “ARID1B is a specific vulnerability in ARID1A-mutant cancers”. Nat. Med., 2014, 20, 251.

[54] Martens J.A., Winston F.: “Recent advances in understanding chromatin remodeling by Swi/Snf complexes”. Curr. Opin. Genet. Dev., 2003, 13, 136.

[55] Nagl N.G. Jr, Patsialou A., Haines D.S., Dallas P.B., Beck G.R. Jr, Moran E.: “The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest”. Cancer. Res., 2005, 65, 9236.

[56] Shen J., Peng Y., Wei L., Zhang W., Yang L., Lan L., et al.: “ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors”. Cancer. Discov., 2015, 5, 752.

[57] Chandler R.L., Damrauer J.S., Raab J.R., Schisler J.C.,Wilkerson M.D., Didion J.P., et al.: “Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling”. Nat. Commun., 2015, 6, 6118.